Mankind Pharma FY25: Strong Growth & Expansion

  Published 1 year ago

Mankind Pharma reported strong Q4 FY25 results with 27.19% revenue growth to Rs 3,079.37 crore, despite a 9.87% drop in profit before tax. Export revenue doubled, fueled by new launches and BSV consolidation with strategic initiatives underway for long term growth.

  • Revenue up 27.19% YoY to Rs 3,079.37 crore.
  • Export revenue doubled, driven by BSV & launches.
  • Focus on chronic, OTC, & BSV portfolios for growth.

You might like these

Citi Sees Q2 Gains for Indian OMCs

MCX Surges 3% on SEBI Approval, Hits 9-Session High

Oberoi Realty Q1 PBT Falls 35%

Karnataka Bank Names Interim CEO

Borosil Posts Loss, Plans Fundraise

Airtel's Xtelify Launches Cloud, AI Platforms

Indian Markets Flat Amid Fed Uncertainty

News that matters the most ⚡